Trials / Active Not Recruiting
Active Not RecruitingNCT05882045
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,800 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Retatrutide | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2023-05-30
- Primary completion
- 2026-04-01
- Completion
- 2026-05-01
- First posted
- 2023-05-31
- Last updated
- 2025-07-23
Locations
169 sites across 10 countries: United States, Argentina, Australia, Canada, Hungary, Mexico, Poland, Puerto Rico, Slovakia, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05882045. Inclusion in this directory is not an endorsement.